On Sept. 7, 2022, Quest Diagnostics announced that it had received emergency use authorization (EUA) from the U.S. Food and Drug Administration for the company’s lab-developed molecular diagnostic test to aid in the diagnosis of infection with the Monkeypox virus. The EUA was the first granted to a commercially available monkeypox test in the United States.